Navigation Links
NSAIDs: Painkillers, inflammation inhibitors, anti-cancer drugs and new de-methylating agents
Date:3/26/2008

Researchers at the National Sun Yat-Sen University and Kaohsiung Medical University, Kaohsiung, Taiwan have revealed a new mechanism by which nonsteroidal anti-inflammatory drugs (NSAIDs) attenuate tumor invasion and metastasis. The research, to be published in the April 2008 issue of Experimental Biology and Medicine, provides new insights for the understanding of the anti-cancer effects of NSAIDs.

NSAIDs have been used for the suppression of pain and inflammation in the clinic for many years. The main targets of these drugs are cyclooxygenases (COXs) which play critical roles in maintaining physiological homeostasis, mediating inflammatory reactions and promoting tumorigenesis. However, COX-independent effects are also important for the inhibition of cancer development by NSAIDs. Indeed, NSAIDs are considered as a novel class of effective chemopreventive drugs.

The research team, led by Wen-Chun Hung, Dean of College of Science, National Sun Yat-Sen University, and a recent doctorial graduate Mei-Ren Pan and two collaborators Hui-Chiu Chang and Lea-Yea Chuang of Kaohsiung Medical University found that NSAIDs up-regulated several anti-metastatic genes including secreted protein acidic and rich in cysteine (SPARC), thrombospindin-1 (TSP-1), TSP-3 and tissue inhibitors of metalloproteinase-2 (TIMP-2) in human lung cancer cells. Our functional assay suggested that increases of SPARC and other anti-metastatic genes were important for NSAIDs to inhibit tumor invasion and metastasis said Wen-Chun Hung. More importantly, we elucidated the underlying mechanism and demonstrated that up-regulation of SPARC in human lung cancer cells was mediated via inhibition of DNA methyltransferases (DNMTs) expression and promoter de-methylation. This is the first report to show that NSAIDs may inhibit the expression of DNMTs to reverse promoter methylation and to reactivate gene transcription.

The researchers say that hypermethylation of tumor suppressor genes is frequently found in many types of human cancer and is a crucial step for tumorigenesis. Recently, a number of de-methylating agents have been reported to exhibit potent anti-cancer effects in vitro and in vivo. Therefore, these agents are considered to be useful for cancer therapy. As a matter of fact, two de-methylating drugs 5-Azacitidine and 5-Aza-2-deoxycytidine (decitabine) have been approved for the treatment of myelodysplastic syndromes, a heterogenous group of hematopoietic stem cell disorders that are multifactorial in their etiology. Hung says our results indicate that NSAIDs may function as de-methylating agents via inhibition of DNMTs and may provide a new strategy for the treatment or prevention of cancer. Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine, agrees and said These unique findings by Dr. Hung and colleagues suggest an entirely new function for non-steroidal anti-inflamatory drugs in cancer therapy. This is an exciting advance for the field of Cancer biology.


'/>"/>

Contact: Dr. Wen-Chung Hung
hung1228@ms10.hinet.net
886-752-52000 x5817
Society for Experimental Biology and Medicine
Source:Eurekalert

Related medicine news :

1. Cerimon to Conduct a Proof of Concept Study for Basiliximab for Noninfectious Uveitis, a Potentially Sight-Threatening Inflammation of the Eye
2. Sirion Therapeutics Receives NDA Acceptance and Priority Review From the FDA for Durezol(TM) in the Treatment of Postoperative Ocular Inflammation
3. A Once-Daily Oral Drug for Chronic Obstructive Pulmonary Disease That Treats COPD-Related Inflammation Could Achieve Blockbuster Status
4. Overweight Hispanic children shown to have vascular inflammation
5. Anti-Inflammatory Drug Improves Glycemia, Lowers Inflammation in Obese, Young Adults
6. TNF-alpha antagonist stops inflammation-induced colon cancer in its tracks
7. Cell-death receptor links cancer susceptibility and inflammation
8. iNOS expression may links chronic biliary inflammation to malignant transformation
9. Diabetes Linked to Blood Vessel Inflammation
10. Low-carb diet reduces inflammation and blood saturated fat in metabolic syndrome
11. Researchers develop powerful tool to study the genetics of inflammation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... Switzerland (PRWEB) , ... May 31, 2016 , ... The ... this model in their laboratories as well. However, laboratories have different challenges compared to ... benefits of lean operations in the lab, METTLER TOLEDO has developed the Lean ...
(Date:5/31/2016)... ... , ... Spectrum Aquatics has launched a brand new ADA pool lift, the ... the user in mind. , “Over the last two years our key customers and ... lbs lift is a necessary requirement for certain facilities with specific needs,” said Nabil ...
(Date:5/31/2016)... ... ... In a recent interview on The Greenburgh Report radio show hosted by Greenburgh, NY ... AM), leading medical insurance advocate Adria Goldman Gross discussed several eye-opening issues that have ... During the interview with Mr. Feiner that aired on May 7, 2016, Ms. Gross, ...
(Date:5/31/2016)... ... May 31, 2016 , ... CURE Media Group ... cancer, has added Cancer and Careers to its Advocacy Spotlight ... on continuing successful careers while fighting cancer. , As partners, both organizations will ...
(Date:5/30/2016)... ... May 30, 2016 , ... Shaolin ... warrior 8-day-8 and 8-night special intensive summer training camp starts on June 17th ... camp offers families and children a fun and unique experience with an opportunity ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... , May 27, 2016 According ... of hypertension is driving ambulatory blood pressure monitoring system ... elasticity and their ability to respond to different pressure ... condition can lead to various cardiovascular disorders such as ... disease. These diseases are growing in prevalence each year. ...
(Date:5/26/2016)... , May 26, 2016 According ... "Medical Waste Management Market - U.S. Industry Analysis, Size, Share, ... management market in the U.S. was valued at US$ 5.89 ... CAGR of 3.4% from 2015 to 2023 to reach US$ ... analysis of current and emerging needle free drug delivery devices ...
(Date:5/25/2016)... FDA 510(k) clearance covers ... for urological and surgical applications Mauna ... Cellvizio®, the multidisciplinary confocal laser endomicroscopy (CLE) platform, ... US with the 12 th 510(k) clearance ... This new FDA clearance covers Confocal Miniprobes indicated ...
Breaking Medicine Technology: